Trial · NCT07886372
Effects of Mango on Insulin Sensitivity in Prediabetes
NCT07886372, Not applicable, Not yet recruiting, Clinical Nutrition Research Center, Illinois Institute of Technology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Mango on Insulin Sensitivity in Prediabetes. Trials, record NCT07886372. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886372
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Mango on Insulin Sensitivity in Prediabetes
- NCT number
- NCT07886372
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 64 participants, estimated
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
- Conditions
- Pre Diabetes
- Interventions
- Mango juice, Control Beverage
- First posted
- 2026-10-21
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fasting Plasma Glucose Concentration | Baseline and Week 6 | Fasting plasma glucose concentration will be measured in plasma samples using a Randox automated clinical analyzer. |
| Primary | Fasting Plasma Insulin Concentration | Baseline and Week 6 | Fasting plasma insulin concentration will be measured in plasma samples using a Randox automated clinical analyzer. |
| Primary | Insulin Sensitivity | Baseline and Week 6 | The Matsuda index for insulin sensitivity will be calculated using validated equations based on paired glucose and insulin values obtained during the Liquid Meal Tolerance Test (LMTT). |
| Secondary | Plasma Glutathione Peroxidase Activity | Baseline and Week 6 | Plasma glutathione peroxidase activity will be measured to assess systemic antioxidant enzyme activity before and after the intervention. |
| Secondary | Plasma Superoxide Dismutase Activity | Baseline and Week 6 | Plasma superoxide dismutase activity will be measured to assess systemic antioxidant enzyme activity before and after the intervention. |
| Secondary | Expression of Nrf-2 Pathway Genes | Baseline and Week 6 | Relative expression of target genes (Nrf-2, glutathione peroxidase 2 \[GLx2\], glutathione S-transferase \[GST\], and NAD(P)H:quinone oxidoreductase-1 \[NQO1\]) will be quantified from blood collected in Paxgene tubes using qPCR. |
| Secondary | Continuous Glucose Monitoring (CGM) | 7-day monitoring periods at baseline and Week 6 | Interstitial glucose profiles will be captured using a continuous glucose monitor worn for 7-days before the LMTT. |
| Secondary | Fasting Plasma Triglyceride Concentration | Baseline and Week 6 | Fasting plasma triglyceride concentration will be measured in plasma samples using a Randox automated clinical analyzer. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886372
GET https://conductscience.org/api/trials/v1/NCT07886372/registered